Download PDF
Thromb Haemost 1999; 82(01): 30-34
DOI: 10.1055/s-0037-1614625
Rapid Communication
Schattauer GmbH

Dermatan Sulphate for the Prevention of Postoperative Venous Thromboembolism in Patients with Cancer

Valerio Di Carlo
1   From the Dipartimento di Chirurgia, IRCCS Ospedale San Raffaele, Università di Milano, Milano, Italy
,
Giancarlo Agnelli
2   Istituto di Medicina Interna e Medicina Vascolare, Università di Perugia, Milano, Italy
,
Paolo Prandoni
3   Istituto di Semeiotica Medica, Università di Padova, Firenze, Milano, Italy
,
Sergio Coccheri
4   Cattedra e Divisione di Angiologia, Università di Bologna, Firenze, Milano, Italy
,
Gian Franco Gensini
5   U. O. di Clinica Medica e Cardiologia, Università di Firenze, Azienda Ospedaliera Careggi, Firenze, Milano, Italy
,
Francesco Gianese
6   Dipartimento Medico, Mediolanum Farmaceutici, Milano, Italy
,
Pier Mannuccio Mannucci
7   Centro Emofilia e Trombosi “A. Bianchi Bonomi”, IRCCS Ospedale Maggiore, Milano, Italy
,
for the “DOS” (Dermatan sulphate in Oncologic Surgery) Study Group › Author AffiliationsStudy monitoring and statistical data handling were performed by Medicina Domani Pharma, Milano (L. M. Fuccella, R. Lepore) and Genova (L. Menta). The study was supported in part by a grant from Mediolanum Farmaceutici, Milano.
Further Information

Publication History

Received 25 January 1999

Accepted after revision 15 April 1999

Publication Date:
11 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Background: Patients undergoing surgery for cancer are at high risk for venous thromboembolism (VTE). Agents that selectively inhibit thrombin, such as dermatan sulphate, have potential for a favourable benefit-risk ratio in the prevention of this complication.

Methods: Patients scheduled for elective abdominal, thoracic, gynecologic or urologic surgery for cancer resection, were randomised to dermatan sulphate (600 mg intramuscularly on the second day before surgery, then 300 mg once daily), or calcium heparin (5,000 IU subcutaneously t.i.d., starting 2 hours before operation). Both treatments were continued until postoperative day 7 or until adequate mobilisation was achieved. Bilateral venography was scheduled at the end of treatment. Venograms were centrally assessed in blind conditions. The study outcomes were VTE (venographically proven deep vein thrombosis [DVT] or symptomatic, objectively confirmed pulmonary embolism) and bleeding complications.

Results: At 27 centres, 842 patients were randomised and underwent surgery (418 dermatan sulphate, 424 heparin). Efficacy was assessed in 521 patients with adequate venography and/or confirmed pulmonary embolism. DVT was observed in a total of 96 patients; symptomatic non-fatal pulmonary embolism developed in 2 patients (one per group), who also had DVT at venography. Postoperative VTE occurred in 40 of 267 patients on dermatan sulphate, 15.0%, versus 56 of 254 patients on heparin, 22.0% (p = 0.033). Relative risk reduction was 32.7% (95% confidence interval, 3.1 to 53.2%). The rate of bleeding complications in all operated patients was 6.9% with dermatan sulphate and 7.5% with heparin (confidence interval for the absolute risk difference, -4.1 to 2.9%). The inhospital mortality rate was 1.2% and 1.4%, respectively.

Conclusions: In oncologic surgery, dermatan sulphate prevents VTE more effectively than heparin without increasing bleeding complications.

 

  • References

  • 1 Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 1997; 78: 126-32.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Levine M. Cancer patients In:. Prevention of venous thromboembolism Goldhaber SZ. ed. New York: Marcel Dekker; 1993: 463-83.
    Google Scholar
  • 3 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. Arch Surg 1992; 127: 310-3.
    CrossrefPubMedGoogle Scholar
  • 4 Clagett GP, Anderson FA, Geerts W, Heit J, Knudson M, Lieberman JR, Merli GJ, Wheeler HB. Prevention of venous thromboembolism. Chest 1998; 114: 531S-60S.
    CrossrefPubMedGoogle Scholar
  • 5 Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331: 1630-41.
    CrossrefPubMedGoogle Scholar
  • 6 Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227-40.
    CrossrefPubMedGoogle Scholar
  • 7 ENOXACAN Study Group. The efficacy and safety of enoxaparin vs un-fractionated heparin for prevention of deep vein thrombosis in elective cancer surgery. A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099-103.
    CrossrefPubMedGoogle Scholar
  • 8 McLeod RS, Geerts WH, Sniderman K, Greenwood C. et al. Thromboprophylaxis after colorectal surgery – results of a randomized, double-blind comparison of low dose heparin and enoxaparin. Thromb Haemost 1997; supplement 753 abstract PD-3078.
    PubMedGoogle Scholar
  • 9 The European Fraxiparine Study Group Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988; 75: 1058-63.
    CrossrefPubMedGoogle Scholar
  • 10 Bergqvist D, Burmark U, Frisell J, Guilbaud O. et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before general abdominal surgery: a comparison with low-dose heparin. Semin Thromb Hemost 1990; 16 (Suppl) 19-24.
    PubMedGoogle Scholar
  • 11 Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, Van Rij AM, Prentice CR, Ten Cate JW. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995; 169: 567-71.
    CrossrefPubMedGoogle Scholar
  • 12 Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-6.
    CrossrefPubMedGoogle Scholar
  • 13 Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical interventions: update of previous meta-analyses. Br J Surg 1997; 84: 750-9.
    CrossrefPubMedGoogle Scholar
  • 14 Tollefsen DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6.
    PubMedGoogle Scholar
  • 15 Bendayan P, Boneu B, Boccalon H. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than un-fractionated and low molecular weight heparins. Thromb Haemost 1994; 71: 576-80.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Agnelli G, Gianese F. Dermatan sulfate: biological and pharmacological properties; clinical applications. In:. Prevention of venous thromboembolism Goldhaber SZ. ed Marcel Dekker; New York: 1993: 287-313.
    Google Scholar
  • 17 Carrié D, Caranobe C, Gabaig AM, Larroche M, Boneu B. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 1992; 68: 637-41.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Matthiasson SE, Lindblad B, Stjernquist U, Bergqvist D. The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 1995; 25: 203-11.
    PubMedGoogle Scholar
  • 19 Cohen AT, Phillips MJ, Edmondson RA, Skinner JA, Das SK, Cooper DJ, Thomas EM, Melissari E, Kakkar VV. A dose ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty. Thromb Haemost 1994; 72: 793-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Agnelli G, Cosmi B, Di Filippo P, Ranucci V. et al. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992; 67: 203-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Prandoni P, Meduri F, Cuppini S, Toniato A, Zangrandi F, Polistena P, Gianese F, Maffei Faccioli A. Dermatan sulfate: a safe approach to prevention of postoperative deep vein thrombosis. Br J Surg 1992; 79: 505-9.
    CrossrefPubMedGoogle Scholar
  • 22 Imbimbo BP, Sié P, Agnelli G, Saivin S, Dupouy D, Damiani M, Houin G, Gianese F. Intramuscular dermatan sulfate MF701 in patients with hip fracture: relationship between pharmacokinetics and antithrombotic efficacy. Thromb Haemost 1994; 71: 553-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-44.
    CrossrefPubMedGoogle Scholar
  • 24 PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism Results of the prospective investigation of pulmonary embolism diagnosis. JAMA 1990; 263: 2753-9.
    CrossrefPubMedGoogle Scholar
  • 25 Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978; 62: 1037-40.
    PubMedGoogle Scholar
  • 26 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162-73.
    CrossrefPubMedGoogle Scholar
  • 27 Lohr JM, James KV, Deshmukh RM, Hasselfeld KA. Calf vein thrombi are not a benign finding. Am J Surg 1995; 170: 86-90.
    CrossrefPubMedGoogle Scholar
  • 28 Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Bucknall T, Stevens J, Porteous F. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double. blind, randomised, multicentre comparison. Thromb Haemost 1993; 70: 562-7.
    Article in Thieme ConnectPubMedGoogle Scholar